IRLA · Forms 3, 4, 5
Insider trades at IRulya Therapeutics
No open-market insider buys or sells at IRulya Therapeutics in the last 90 days; 6 filings reported awards, option exercises, tax withholding or new insiders.
Every Form 3, 4 and 5 filed for IRulya Therapeutics (IRLA) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Insider trades in the last 90 days
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Catherine M. Bonuccelli | Director | Became an insider (Form 3) | Form 3 | ||||
| James Elwood Valentine | Director | Became an insider (Form 3) | Form 3 | ||||
| John Drayton Wise | Director | Became an insider (Form 3) | Form 3 | ||||
| John Militello | Chief Financial Officer | Became an insider (Form 3) | Form 3 | ||||
| Keith R. Fandrick | Chief Operating Officer | Became an insider (Form 3) | Form 3 | ||||
| Leone D Patterson | Director | Became an insider (Form 3) | Form 3 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.